retatrutide triple agonist peptide Retatrutide: The first-in-class investigational triple

A case study exploring the efficacy of exenatide therapy in a 59-year-old NAFLD patient, reported a 73% reduction in hepatic fat content and significant improvements in liver enzymes 44 weeks post-treatment [20]

If GLP-1 medications caused thyroid problems in humans at meaningful rates, a study this large and long would have detected it

[13] [14] The UK Chief Medical Officers recommend at least 150 minutes of moderate-intensity activity or 75 minutes of vigorous-intensity activity weekly, along with strength exercises on two or more days

It is plausible that retatrutide could offer similar benefits in this group given its potent metabolic effects, but this has not been directly studied